Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial (vol 12, 104, 2023)

被引：0
|
作者：
Zakaraia, Haitham G. [1 ]
Salem, Heba F. [2 ]
Mostafa, Mostafa A. A. [3 ]
Ali, Ahmed M. [4 ]
Rabea, Hoda M. [5 ]
机构：
[1] Univ Sadat City, Fac Pharm, Clin Pharm Dept, POB 32897, Sadat City, Menoufia, Egypt
[2] Beni Suef Univ, Fac Pharm, Pharmaceut & Ind Pharm Dept, POB 62514, Bani Suwayf, Egypt
[3] October 6 Univ, Fac Med, Internal Med Dept, POB 12585, Giza, Egypt
[4] October 6 Univ, Fac Pharm, Clin Pharm Dept, POB 12585, Giza, Egypt
[5] Beni Suef Univ, Fac Pharm, Clin Pharm Dept, POB 62514, Bani Suwayf, Egypt
来源：
BENI-SUEF UNIVERSITY JOURNAL OF BASIC AND APPLIED SCIENCES | 2024年 / 13卷 / 01期
关键词：
D O I：
10.1186/s43088-024-00487-9
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial
    Haitham G. Zakaraia
    Heba F. Salem
    Mostafa A. A. Mostafa
    Ahmed M. Ali
    Hoda M. Rabea
    Beni-Suef University Journal of Basic and Applied Sciences, 12
  • [2] Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial
    Zakaraia, Haitham G.
    Salem, Heba F.
    Mostafa, Mostafa A. A.
    Ali, Ahmed M.
    Rabea, Hoda M.
    BENI-SUEF UNIVERSITY JOURNAL OF BASIC AND APPLIED SCIENCES, 2023, 12 (01)
  • [3] Correction: Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial
    Haitham G. Zakaraia
    Heba F. Salem
    Mostafa A. A. Mostafa
    Ahmed M. Ali
    Hoda M. Rabea
    Beni-Suef University Journal of Basic and Applied Sciences, 13
  • [4] Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial
    Softeland, Eirik
    Meier, Juris J.
    Vangen, Bente
    Toorawa, Robert
    Maldonado-Lutomirsky, Mario
    Broedl, Uli C.
    DIABETES CARE, 2017, 40 (02) : 201 - 209
  • [5] Adding empagliflozin to sitagliptin plus metformin vs. adding sitagliptin to empagliflozin plus metformin as triple therapy in Egyptian patients with type 2 diabetes: a 12-week open trial
    Zakaraia, H. G.
    Salem, H. F.
    Mostafa, M. A. A.
    Ali, A. M.
    Rabea, H.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (15) : 7289 - 7298
  • [6] Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder:: A randomized, open-label, 12-week, parallel-group trial
    Han, Changsu
    Pae, Chi-Un
    Lee, Bun Hee
    Ko, Young-Hoon
    Masand, Prakash S.
    Patkar, Ashwin A.
    Jung, In-Kwa
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2008, 32 (02): : 437 - 444
  • [7] Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-Naive Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial
    Ito, Daisuke
    Inoue, Kazuyuki
    Saito, Daigo
    Hamaguchi, Keiko
    Kaneko, Kimie
    Sumita, Takashi
    Inukai, Kouichi
    Inoue, Ikuo
    Shimada, Akira
    DIABETES THERAPY, 2021, 12 (12) : 3201 - 3215
  • [8] Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder - A 12-week prospective, open-label, randomized, parallel-group trial
    Han, Changsu
    Pae, Chi-Un
    Lee, Bun-Hee
    Ko, Young-Hoon
    Masand, Prakash S.
    Patkar, Ashwin A.
    Joe, Sook-Haeng
    Jung, In-Kwa
    CLINICAL DRUG INVESTIGATION, 2008, 28 (04) : 251 - 261
  • [9] Venlafaxine versus Mirtazapine in the Treatment of Undifferentiated Somatoform DisorderA 12-Week Prospective, Open-Label, Randomized, Parallel-Group Trial
    Changsu Han
    Chi-Un Pae
    Bun-Hee Lee
    Young-Hoon Ko
    Prakash S. Masand
    Ashwin A. Patkar
    Sook-Haeng Joe
    In-Kwa Jung
    Clinical Drug Investigation, 2008, 28 : 251 - 261
  • [10] Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial
    Han, Kyung-Ah
    Chon, Suk
    Chung, Choon Hee
    Lim, Soo
    Lee, Kwan-Woo
    Baik, SeiHyun
    Jung, Chang Hee
    Kim, Dong-Sun
    Park, Kyong Soo
    Yoon, Kun-Ho
    Lee, In-Kyu
    Cha, Bong-Soo
    Sakatani, Taishi
    Park, Sumi
    Lee, Moon-Kyu
    DIABETES OBESITY & METABOLISM, 2018, 20 (10): : 2408 - 2415
12345